Taysha Gene Therapies
TSHA
4.43
+0.04
+0.91%
Taysha Gene Therapies
US · TSHA
#3015 by market cap
Listed 2020
4.43
+0.04
+0.91%
Live - 5344 symbols - heartbeat 363s ago
· 2026-10-08 04:03
Pre-market
4.41
-0.45%
After-hours
4.43
0.00%
- Market cap
- 1.44B
- P/E (TTM)i
- -10.80
- P/Bi
- 3.73
- EPSi
- -0.34
- Div yieldi
- 0.00%
- 52W posi
- 20%
Reader sentiment
Are you bullish or bearish on TSHA?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 1 in the most recent period (2026/Q3).
- Total institutional ownership fell 5.3 percentage points.
Institutional ownership
- Held by institutions
- 93.68% -5.31pp
- Institutions
- 245 -1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund35.53%
Hedge Fund29.74%
VC/PE Fund15.03%
Public Company10.55%
Individual/Insider8.07%
Government Pension Fund1.39%
Sovereign Wealth Fund0.69%
Private Company0.42%
Family Office/Trust0.32%
Top holders as of 2026-06-30
Avoro Capital Advisors LLC
7.33% · 23.89M sh
RA Capital Management, L.P.
7.23% · 23.56M sh
Paul Manning
6.98% · 22.74M sh
BlackRock
6.35% · 20.69M sh
Vestal Point Capital, LP
5.96% · 19.42M sh
Morgan Stanley
4.99% · 16.24M sh
Vanguard Capital Management, LLC
4.41% · 14.38M sh
The Goldman Sachs Group, Inc.
4.17% · 13.58M sh
RTW Investments, LP
4.16% · 13.56M sh
FMR
4.09% · 13.34M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 25 buys · 25 sells
| Name | Role | Stake |
|---|---|---|
| Paul Manning | Board Observer | 6.98% |
| Sean Stalfort | Independent Director | 0.63% |
| Sean Nolan | Chairperson & CEO | 0.20% |
| Kamran Alam | Chief Financial Officer | 0.14% |
| Phillip Donenberg | Independent Director | 0.07% |
| Laura Sepp-Lorenzino | Independent Director | 0.03% |
| Alison Long | Director | 0.03% |
| Sukumar Nagendran | President, Head of Research & Development and Director | -- |
| Sean McAuliffe | Chief Business Officer | -- |
| Tiger Lily Capital | -- | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-07-09 | Sukumar Nagendran | President, Head of Research & Development and Director | Automatic Disposition | -200,000 | $6.24 |
| 2026-05-31 | Phillip Donenberg | Independent Director | Other Acquisition | +21,335 | -- |
| 2026-05-31 | Phillip Donenberg | Independent Director | Other Derivative Acquisition | +42,671 | $5.97 |
| 2026-05-31 | Sean Stalfort | Independent Director | Other Acquisition | +21,335 | -- |
| 2026-05-31 | Sean Stalfort | Independent Director | Other Derivative Acquisition | +42,671 | $5.97 |
| 2026-05-31 | Laura Sepp-Lorenzino | Independent Director | Other Acquisition | +21,335 | -- |
| 2026-05-31 | Laura Sepp-Lorenzino | Independent Director | Other Derivative Acquisition | +42,671 | $5.97 |
| 2026-05-31 | Alison Long | Director | Other Acquisition | +21,335 | -- |
| 2026-05-31 | Alison Long | Director | Other Derivative Acquisition | +42,671 | $5.97 |
| 2026-04-09 | Sukumar Nagendran | President, Head of Research & Development and Director | Automatic Disposition | -180,979 | $4.46 |
| 2026-04-09 | Sukumar Nagendran | President, Head of Research & Development and Director | Derivative Exercise and Sale | -19,021 | $1.71–4.46 |
| 2026-02-26 | Rumana Haque-Ahmed | Chief Regulatory Officer | Intent to Sell (Form 144) | -2,405 | $4.57 |
| 2026-02-03 | Sean McAuliffe | Chief Business Officer | Intent to Sell (Form 144) | -914 | $4.72 |
| 2026-02-03 | Kamran Alam | Chief Financial Officer | Open Market Disposition | -1,655 | $4.52 |
| 2026-02-03 | Rumana Haque-Ahmed | Chief Regulatory Officer | Intent to Sell (Form 144) | -697 | $4.72 |
| 2026-01-25 | Sean Nolan | Chairperson & CEO | Open Market Disposition | -178,101 | $4.61–4.75 |
| 2026-01-25 | Sukumar Nagendran | President, Head of Research & Development and Director | Open Market Disposition | -116,050 | $4.61–4.75 |
| 2026-01-25 | Kamran Alam | Chief Financial Officer | Open Market Disposition | -102,817 | $4.61–4.75 |
| 2026-01-22 | Sean Nolan | Chairperson & CEO | Intent to Sell (Form 144) | -168,078 | $5.09 |
| 2026-01-22 | Sukumar Nagendran | President, Head of Research & Development and Director | Intent to Sell (Form 144) | -113,824 | $5.09 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 04:03:15 · For reference only, not investment advice and not tailored to your situation.